Published in J Alzheimers Dis on January 01, 2010
Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener (2014) 1.09
Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.95
Mild cognitive impairment and its management in older people. Clin Interv Aging (2015) 0.93
Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem (2014) 0.93
Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Transl Psychiatry (2011) 0.86
APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener (2015) 0.85
Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neurol (2011) 0.80
A Triple Network Connectivity Study of Large-Scale Brain Systems in Cognitively Normal APOE4 Carriers. Front Aging Neurosci (2016) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 21.70
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet (1998) 7.26
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J Biol Chem (1990) 5.91
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Sortilin is essential for proNGF-induced neuronal cell death. Nature (2004) 5.62
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Reconstitution of gamma-secretase activity. Nat Cell Biol (2003) 4.66
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet (2006) 4.51
Apolipoprotein E polymorphism and Alzheimer's disease. Lancet (1993) 4.47
APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology (1999) 4.37
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature (1994) 4.28
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.07
Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 3.92
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet (1996) 3.58
Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology (2002) 3.57
Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis (2000) 3.46
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet (2003) 3.00
Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol (1995) 2.86
Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron (2006) 2.76
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol (2007) 2.70
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol (1998) 2.53
Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet (2007) 2.51
Worldwide prevalence and incidence of dementia. Drugs Aging (1999) 2.50
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.43
Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol (1988) 2.38
Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol (1994) 2.25
The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet (2000) 2.24
Heritability of lobar brain volumes in twins supports genetic models of cerebral laterality and handedness. Proc Natl Acad Sci U S A (2002) 2.24
The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol (2007) 2.21
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest (1999) 2.21
Common principles in clathrin-mediated sorting at the Golgi and the plasma membrane. Biochim Biophys Acta (2005) 2.11
GGA proteins mediate the recycling pathway of memapsin 2 (BACE). J Biol Chem (2004) 1.99
Non-familial Alzheimer's disease is mainly due to genetic factors. J Alzheimers Dis (2002) 1.95
Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology (2008) 1.91
The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet (1991) 1.88
Accuracy of clinical diagnosis of Alzheimer's disease. BMJ (1990) 1.84
Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.84
Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem (1996) 1.79
Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77
Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology (2006) 1.75
Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol (2000) 1.74
Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol (1996) 1.74
Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees. Am J Hum Genet (1999) 1.72
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2007) 1.67
Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol (1996) 1.66
Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. Hum Mol Genet (2003) 1.65
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology (1996) 1.62
Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol (2007) 1.61
Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry (1996) 1.60
SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat (2008) 1.59
Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport (2007) 1.57
Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology (2001) 1.57
The apolipoprotein E epsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry (2002) 1.57
Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry (2002) 1.55
A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet (2007) 1.55
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging (2001) 1.52
Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ (2004) 1.52
Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet (2004) 1.51
SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis (2007) 1.49
The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase (2005) 1.49
Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol (2007) 1.45
Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. Neurology (2007) 1.45
Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology (1995) 1.42
SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging (2007) 1.42
Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol (2005) 1.39
Impact of APOE in mild cognitive impairment. Neurology (2004) 1.37
Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem (1998) 1.36
DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet (1992) 1.36
Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am J Hum Genet (2003) 1.35
Sorl1 as an Alzheimer's disease predisposition gene? Neurodegener Dis (2007) 1.31
Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet (1996) 1.30
Novel family-based approaches to genetic risk in thrombosis. J Thromb Haemost (2003) 1.29
Replication study of candidate genes for cognitive abilities: the Lothian Birth Cohort 1936. Genes Brain Behav (2008) 1.29
Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat (2004) 1.25
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Apolipoprotein E, Alzheimer disease, and African Americans. Arch Neurol (2003) 4.63
Mediterranean diet and risk for Alzheimer's disease. Ann Neurol (2006) 4.38
Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13
Hypertension and the risk of mild cognitive impairment. Arch Neurol (2007) 3.62
A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol (2010) 3.52
Stroke and the risk of Alzheimer disease. Arch Neurol (2003) 3.49
Mediterranean diet and mild cognitive impairment. Arch Neurol (2009) 3.40
Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol (2008) 3.39
Imaging hippocampal function across the human life span: is memory decline normal or not? Ann Neurol (2002) 3.34
Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One (2012) 3.11
Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol (2006) 2.98
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Alcohol intake and risk of dementia. J Am Geriatr Soc (2004) 2.90
Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord (2005) 2.88
Hyperinsulinemia and risk of Alzheimer disease. Neurology (2004) 2.87
Relation of diabetes to mild cognitive impairment. Arch Neurol (2007) 2.86
Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology (2005) 2.76
Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol (2008) 2.69
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Mediterranean diet and Alzheimer disease mortality. Neurology (2007) 2.45
Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol (2005) 2.39
Caloric intake and the risk of Alzheimer disease. Arch Neurol (2002) 2.28
Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet (2012) 2.23
The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol (2007) 2.21
Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia. Ann Neurol (2006) 2.21
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol (2003) 2.20
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol (2004) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol (2009) 2.06
Validity of self-reported stroke in elderly African Americans, Caribbean Hispanics, and Whites. Arch Neurol (2009) 2.05
Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet (2011) 2.02
SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol (2011) 2.01
Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep (2004) 2.00
Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol (2012) 1.97
The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol (2008) 1.92
Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol (2010) 1.91
Dietary factors and Alzheimer's disease. Lancet Neurol (2004) 1.90
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Measures of adiposity and dementia risk in elderly persons. Arch Neurol (2007) 1.88
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84
Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol (2010) 1.80
Disparities in the recording of Parkinson's disease on death certificates. Mov Disord (2005) 1.75
Health and function of participants in the Long Life Family Study: A comparison with other cohorts. Aging (Albany NY) (2011) 1.74
Stroke and memory performance in elderly persons without dementia. Arch Neurol (2006) 1.65
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet (2012) 1.63
Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol (2010) 1.61
Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol (2011) 1.59
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport (2007) 1.57
Association of shorter leukocyte telomere repeat length with dementia and mortality. Arch Neurol (2012) 1.55
Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol (2013) 1.52
Imaging the Abeta-related neurotoxicity of Alzheimer disease. Arch Neurol (2007) 1.49
Functional correlates and prevalence of mild parkinsonian signs in a community population of older people. Arch Neurol (2005) 1.48
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc (2005) 1.44
Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. Arch Neurol (2008) 1.44
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 1.44
Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol (2012) 1.44
The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science (2003) 1.40
Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol (2005) 1.39
Parkinsonian signs in older people in a community-based study: risk of incident dementia. Arch Neurol (2004) 1.35
C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol (2013) 1.34
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. Arch Neurol (2002) 1.28
Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology (2003) 1.27
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol (2007) 1.26
Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. J Alzheimers Dis (2011) 1.25
SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One (2013) 1.23
Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer's disease. Neurogenetics (2007) 1.22
Heritability estimates of endophenotypes of long and health life: the Long Life Family Study. J Gerontol A Biol Sci Med Sci (2010) 1.22
Telephone assessment of cognitive function in the late-onset Alzheimer's disease family study. Arch Neurol (2010) 1.22
Association of C-reactive protein with cognitive impairment. Arch Neurol (2010) 1.19
Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol (2007) 1.19
Effect of smoking and time on cognitive function in the elderly without dementia. Neurology (2005) 1.19
Linking hippocampal structure and function to memory performance in an aging population. Arch Neurol (2009) 1.17
Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord (2007) 1.16
Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology (2013) 1.16
TREM2 and neurodegenerative disease. N Engl J Med (2013) 1.15
Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort. Arch Neurol (2011) 1.15
Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain (2010) 1.11
Olfactory identification deficits and MCI in a multi-ethnic elderly community sample. Neurobiol Aging (2008) 1.10
Coding mutations in SORL1 and Alzheimer disease. Ann Neurol (2015) 1.09
Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener (2012) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. Age Ageing (2008) 1.07
Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res (2006) 1.06
Screening for C9ORF72 repeat expansion in FTLD. Neurobiol Aging (2012) 1.05
Acquisition, recall, and forgetting of verbal information in long-term memory by young, middle-aged, and elderly individuals. Cortex (2003) 1.04
Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet (2015) 1.03
Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 1.03
APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol (2004) 1.02